Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply
N Engl J Med
.
2020 Jan 2;382(1):93-94.
doi: 10.1056/NEJMc1915739.
Authors
Bruce E Sands
1
,
Stefan Schreiber
2
,
Richard A Lirio
3
Affiliations
1
Icahn School of Medicine at Mount Sinai, New York, NY bruce.sands@mssm.edu.
2
University Hospital Schleswig-Holstein, Kiel, Germany.
3
Takeda Development Center Americas, Cambridge, MA.
PMID:
31875508
DOI:
10.1056/NEJMc1915739
No abstract available
Publication types
Letter
Comment
MeSH terms
Adalimumab
Antibodies, Monoclonal, Humanized
Colitis, Ulcerative*
Humans
Infliximab
Substances
Antibodies, Monoclonal, Humanized
vedolizumab
Infliximab
Adalimumab